Advancing the public health applications of Chlamydia trachomatis serology

Sarah C. Woodhall*, Rachel J. Gorwitz, Stephanie J. Migchelsen, Sami L. Gottlieb, Patrick J. Horner, William M. Geisler, Catherine Winstanley, Katrin Hufnagel, Tim Waterboer, Diana L. Martin, Wilhelmina M. Huston, Charlotte A. Gaydos, Carolyn Deal, Magnus Unemo, J. Kevin Dunbar, Kyle Bernstein

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

28 Citations (Scopus)

Abstract

Genital Chlamydia trachomatis infection is the most commonly diagnosed sexually transmitted infection. Trachoma is caused by ocular infection with C trachomatis and is the leading infectious cause of blindness worldwide. New serological assays for C trachomatis could facilitate improved understanding of C trachomatis epidemiology and prevention. C trachomatis serology offers a means of investigating the incidence of chlamydia infection and might be developed as a biomarker of scarring sequelae, such as pelvic inflammatory disease. Therefore, serological assays have potential as epidemiological tools to quantify unmet need, inform service planning, evaluate interventions including screening and treatment, and to assess new vaccine candidates. However, questions about the performance characteristics and interpretation of C trachomatis serological assays remain, which must be addressed to advance development within this field. In this Personal View, we explore the available information about C trachomatis serology and propose several priority actions. These actions involve development of target product profiles to guide assay selection and assessment across multiple applications and populations, establishment of a serum bank to facilitate assay development and evaluation, and development of technical and statistical methods for assay evaluation and analysis of serological findings. The field of C trachomatis serology will benefit from collaboration across the public health community to align technological developments with their potential applications.

Original languageEnglish
Pages (from-to)e399-e407
JournalThe Lancet Infectious Diseases
Volume18
Issue number12
DOIs
Publication statusPublished - Dec 2018

Bibliographical note

Funding Information:
Acknowledgments We thank all participants at the Public Health England expert meeting for their contribution to the discussions. We also thank Paula Blomquist and Nastassya Chandra (Public Health England, London, UK) for their assistance with organising and delivering the meeting. The meeting was supported by funds from Public Health England. SCW thanks Anne Johnson (UCL, London, UK), Anthony Nardone and Kate Soldan (Public Health England, London, UK) and Myra McClure (Imperial College London, London, UK) for mentorship, supervision and expert advice received during her PhD and her work with Public Health England, which informed many of the ideas discussed at the meeting and provided motivation for its inception SCW, PJH, and JKD wish to acknowledge support from the National Institute of Health Research Health Protection Research Unit (NIHR HPRU) in Evaluation of Interventions at the University of Bristol and the NIHR HPRU in Blood Borne and Sexually Transmitted Infections at University College London in partnership with Public Health England. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, the UK Department of Health, Public Health England, the US Centers for Disease Control and Prevention, or WHO.

Funding Information:
We thank all participants at the Public Health England expert meeting for their contribution to the discussions. We also thank Paula Blomquist and Nastassya Chandra (Public Health England, London, UK) for their assistance with organising and delivering the meeting. The meeting was supported by funds from Public Health England. SCW thanks Anne Johnson (UCL, London, UK), Anthony Nardone and Kate Soldan (Public Health England, London, UK) and Myra McClure (Imperial College London, London, UK) for mentorship, supervision and expert advice received during her PhD and her work with Public Health England, which informed many of the ideas discussed at the meeting and provided motivation for its inception SCW, PJH, and JKD wish to acknowledge support from the National Institute of Health Research Health Protection Research Unit (NIHR HPRU) in Evaluation of Interventions at the University of Bristol and the NIHR HPRU in Blood Borne and Sexually Transmitted Infections at University College London in partnership with Public Health England. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, the UK Department of Health, Public Health England, the US Centers for Disease Control and Prevention, or WHO.

Funding Information:
WMG has received grants from Genocea Biosciences and Moderna Therapeutics, outside the submitted work. WMH has a pending patent for C trachomatis diagnostic peptide and method (PCT/AU2013/001333). PJH has received personal fees from the Crown Prosecution Service, the British Association for Sexual Health and HIV, grants from Mast Group, and non-financial support from Hologic, outside the submitted work. Additionally, PJH has a patent for a sialidase spot test to diagnose bacterial vaginosis issued to the University of Bristol, Bristol, UK. All other authors declare no competing interests.

Publisher Copyright:
© 2018 Elsevier Ltd

Fingerprint

Dive into the research topics of 'Advancing the public health applications of Chlamydia trachomatis serology'. Together they form a unique fingerprint.

Cite this